In a fruitful 2 year collaboration with CCI, We Discover iteratively designed and delivered a fully customised and globally unique solution that met ZERO's design specifications for analysing and visualising cancer genome data. The new system is secure, scalable, and user-friendly, allowing for the seamless integration of dozens of diverse data sources. We designed a streamlined and intuitive user interface to simplify the analysis of these complex data. Our engagement consisted of the following outputs and deliverables:
- Product Management
- Ran workshops to brainstorm for solution and objectives, frame the platform’s vision, define goals and objectives,
- Mapped the to-be/future state and create a product roadmap
- Collaborated to map user stories
- Refining scope & requirements - to achieve desired outcomes/solutions
- Prioritise product backlog items
- Working with developers on technical feasibility of solutions etc
- Scrum framework - 2 week sprints
- Product Design
- Conducted discovery through research and interviews with users to gain an in-depth understanding of the current process
- Created a process map to visualise as-is state to be able to identify problems in the current state
- Conducted series of workshops and ideation sessions
- Set a weekly cadence of design-feedback-iterate (needs constant validation if data representation etc. or how we understand it are correct)
- Design sprints have to be ahead of dev sprints
- Prototype to present to stakeholders & gather feedback
- Usability testing to get feedback for design iterations & improvements
- Design system?
- Design quality assurance
The design and delivery of ZeroDash has streamlined the data matching, interpretation, and reporting system, significantly reducing hands-on analysis time from 22 hours to 6.5 hours. ZeroDash has also reduced the number of data analysis queries needed to interpret each case. Other significant improvements include:
- Streamlined data curation and interpretation, resulting in a 50% improvement in reporting efficiency and turnaround times.
- Reduced time spent on manual tasks, allowing for the curation of more patients and the ability to undertake additional research projects while keeping up with field developments.
- Streamlined training processes for new staff joining the ZERO program, facilitating rapid scaling on demand.
- The ability to conduct curation training to upskill wider CCI research staff and students, ultimately utilizing multi-omics approaches to address their own research questions.
- Future potential for CCI to offer paid training courses and software licensing opportunities in integrated multi-omics analysis and data curation.
- A fit-for-purpose software solution capable of transitioning from research to clinical-grade testing and reporting in the future.
- Improved risk profile of the program, ultimately benefiting CCI and KCC, due to a higher degree of automation, resulting in reduced human error and more reliable and robust reporting.
- Facilitation of more rapid and meaningful interpretation of data sets, leading to greater clinical impact.
Reduction analysis time
Increase patient enrolment
Mark Cowley - Computational Biology Group Leader
Children Cancer Institute